Search
naloxegol (Movantik)
FDA-approved Sept 2014.
Indications:
- opioid-induced constipation
- number needed to treat to benefit 1 patient = 8
Dosage:
- 12.5-25 mg PO QD
Adverse effects:
- gastrointestinal distress
- abdominal pain, diarrhea, flatulence
- headache
Mechanism of action:
- peripheral mu-opioid receptor antagonist
General
laxative
aromatic compound
opioid receptor antagonist or narcotic antagonist
Database Correlations
PUBCHEM correlations
References
- Chey WD et al
Naloxegol for Opioid-Induced Constipation in Patients with
Noncancer Pain.
N Engl J Med. June 4, 2014
http://www.nejm.org/doi/full/10.1056/NEJMoa1310246
- FDA News Release. September 16, 2014
FDA approves Movantik for opioid-induced constipation
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm414620.htm
- Chey WD, Webster L, Sostek M et al
Naloxegol for opioid-induced constipation in patients with
noncancer pain.
N Engl J Med. 2014 Jun 19;370(25):2387-96. Epub 2014 Jun 4.
PMID: 24896818